Clinical trial NCT00459316 - References

HIV Infections — Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

Citation(s)

•   Campos-Outcalt D
  Meningococcal vaccine: New product, new recommendations. J Fam Pract. 2005 Apr;54(4):324-6. Review.
•   Centers for Disease Control and Prevention (CDC)
  Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006 Oct 20;55(41):1120-4. Erratum in: MMWR Morb Mortal Wkly Rep. 2006 Nov 3;55(43):1177.
•   Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A
  Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13.
•   Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry GK; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team
  Immunogenicit
•   Mehlhorn AJ, Balcer HE, Sucher BJ
  Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine. Ann Pharmacother. 2006 Apr;40(4):666-73. Epub 2006 Mar 7. Review.
•   Pearson IC, Baker R, Sullivan AK, Nelson MR, Gazzard BG
  Meningococcal infection in patients with the human immunodeficiency virus and acquired immunodeficiency syndrome. Int J STD AIDS. 2001 Jun;12(6):410-1.
•   Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Käyhty H
  Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine. 2003 Oct 1;21(27-30):4437-47.
•   Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; IMPAACT P1065 Protocol Team
  Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2
•   Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S; IMPAACT P1065 Protocol Team
  Phase I/II, open-label trial of safety and immunogenicity of meningococcal (g
•   Spector SA, Qin M, Lujan-Zilbermann J, Singh KK, Warshaw MG, Williams PL, Jean-Philippe P, Fenton T, Siberry GK; IMPAACT P1065 Protocol Team
  Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FC? receptor II are associated with antibody res

Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in HIV-Infected Children and Youth And Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth

Details for clinical trial NCT00459316